Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 4:24 PM ET
Aurinia Pharmaceuticals Inc (AUPH) Stock Chart
Aurinia Pharmaceuticals (AUPH) has a latest price of $15.40 on Nov 17, 2026, 20.0% below its 52-week high of $19.25. Its price rose 0.3% over the past 12 months. The month-end price rose 449.5% over the 10 years through Oct 2026, a compound annual rate of 18.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $33.08 in Oct 2021 and its lowest $2.10 in Dec 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart AUPH with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for AUPH.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 4.8%, and over 6 months it fell 1.0%. The month-end price rose 126.8% over the 3 years through Oct 2026, a compound annual rate of 31.4%.
| Period | Change |
|---|---|
| 1 month | -6.6% |
| 3 months | -4.8% |
| 6 months | -1.0% |
| 12 months | +0.3% |
| 12 months, with dividends | +0.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +126.8% | +31.4% |
| 5 years | -49.7% | -12.8% |
| 10 years | +449.5% | +18.6% |
Price by Year
Its best calendar year was 2019, when the price rose 197.1%, and its weakest was 2022, when it fell 81.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $16.65 | +4.4% |
| 2025 | $15.95 | +77.6% |
| 2024 | $8.98 | -0.1% |
| 2023 | $8.99 | +108.1% |
| 2022 | $4.32 | -81.1% |
| 2021 | $22.87 | +65.4% |
| 2020 | $13.83 | -31.7% |
| 2019 | $20.26 | +197.1% |
| 2018 | $6.82 | +50.6% |
| 2017 | $4.53 | +115.7% |
Trading Range
The price is 6.4% below its 50-day average of $16.46 and 2.1% below its 200-day average of $15.74.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $15.40 | |
| 52-week high | $19.25 | -20.0% |
| 52-week low | $13.52 | +13.9% |
| 50-day average | $16.46 | -6.4% |
| 200-day average | $15.74 | -2.1% |
Price Risk
Over 3 years, its largest fall from a peak was 49.3%.
| Measure | Value |
|---|---|
| 1-year beta | 0.67 |
| Largest fall, 1 year | -21.8% |
| Largest fall, 3 years | -49.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About AUPH
What is AUPH's 1-year price change?
Aurinia Pharmaceuticals's price rose 0.3% over the past 12 months. With dividends included, the 12-month total return was 0.3%.
What is AUPH's 5-year price change?
Aurinia Pharmaceuticals's month-end price fell 49.7% over the 5 years through Oct 2026, a compound annual decline of 12.8%. These figures leave out dividends.
What is AUPH's 52-week high and low?
Aurinia Pharmaceuticals's 52-week high is $19.25 and its 52-week low is $13.52. Its latest price of $15.40 on Nov 17, 2026 is 20.0% below the high.
What is AUPH's beta?
Aurinia Pharmaceuticals's 1-year beta against the S&P 500 is 0.67, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 21.8%.
Is the AUPH chart free?
Yes. Advanced Charting for AUPH is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
AUPH pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors